Pharmaceutical

Filter

Current filters:

None

Popular Filters

1 to 25 of 6955 results

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

24-07-2014

US biotech firm Biogen Idec said that the European Commission has approved its subcutaneous injectable…

Biogen IdecCytokinesMultiple sclerosisNeurologicalPharmaceuticalPlegridyRegulationUSA

Currency takes toll on Roche first-half results

24-07-2014

Swiss pharma major Roche, the world’s leading oncology company, this morning posted first-half 2014…

FinancialOncologyPharmaceuticalRoche

GlaxoSmithKline slashes forecast as 2nd-qtr sales and earnings fall sharply

GlaxoSmithKline slashes forecast as 2nd-qtr sales and earnings fall sharply

23-07-2014

UK pharma giant GlaxoSmithKline saw its shares fall 3.9% to £45.94 shortly after the company reported…

FinancialFluticasone propionateGlaxoSmithKlinePharmaceuticalPulmonologyUK

Expert View: Has UK pharma lost its Euro-vision?

Expert View: Has UK pharma lost its Euro-vision?

23-07-2014

Former AstraZeneca serialization expert, Christoph Krähenbühl, demystifies the arguments around compliance…

EuropeEuropean UnionMarkets & MarketingMedicines verification infrastructurePharmaceuticalResearchUK

UCB reports positive Phase III results for brivaracetam in epilepsy

UCB reports positive Phase III results for brivaracetam in epilepsy

23-07-2014

Belgian drugmaker UCB says its Phase III study of brivaracetam has shown the drug reduced partial-onset…

BelgiumBRIVARACETAMEpilepsyNeurologicalPartial-onset seizurePharmaceuticalResearchUCB

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

23-07-2014

The National Institute for Health and Care Excellence (NICE), the UK’s health care guidance body, has…

Acute coronary syndromesCardio-vascularEfientEli LillyPharmaceuticalprasugrelRegulationUK

NICE recommends Amitiza to treat long-term, painful constipation

NICE recommends Amitiza to treat long-term, painful constipation

23-07-2014

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Amitiza (lubiprostone)…

AmitizaGastro-intestinalsGastroenterologyPharmaceuticalRegulationSucampoUK

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

23-07-2014

The UK’s National Institute for Health and Care Excellence (NICE) has issued guidance recommending…

Astellas PharmaBristol-Myers SquibbOncologyPharmaceuticalRegulationUKXtandiYervoy

Merck strengthens commitment to Chinese growth market

Merck strengthens commitment to Chinese growth market

23-07-2014

Germany’s Merck KGaA, a leading company for high-tech products in the pharmaceutical and chemical sectors,…

ChinaFinancialMerckMerck KGaAPharmaceuticalProductionResearch

Novasep sites approved by US FDA

Novasep sites approved by US FDA

22-07-2014

French active ngredients company Novasep has successfully completed US Food and Drug Administration pre-approval…

Active pharmaceutical ingredientFranceNovasepPharmaceuticalRegulationUSA

New cancer drugs approvals in Canada delayed due to extra layer of bureaucratic review

New cancer drugs approvals in Canada delayed due to extra layer of bureaucratic review

21-07-2014

The organization that reviews oncology medicines in Canada may unnecessarily delay approvals while cancer…

BevacizumabCanadaFraser InstituteOncologyPharmaceuticalRegulation

Allergan reports strong 2nd-qtr figures but still plan to cut 1,500 jobs worldwide

Allergan reports strong 2nd-qtr figures but still plan to cut 1,500 jobs worldwide

21-07-2014

Botox maker Allergan has reported its second quarter operating results while also announcing that it…

AllerganAllerganBotoxFinancialPharmaceuticalUSA

Milestone appoints Francis Plat as chief medical officer

Milestone appoints Francis Plat as chief medical officer

21-07-2014

Quebec-based cardiovascular drug development specialist Milestone Pharmaceuticals has announced the appointment…

BoardroomCanadaCardio-vascularFrancis PlatMilestone PharmaceuticalsPharmaceutical

Expensive new hepatitis C drugs are worth the investment

Expensive new hepatitis C drugs are worth the investment

21-07-2014

The debate over the high price of new Hepatitis C Virus (HCV) drugs has focused on the price per pill,…

Anti-viralsCVS CaremarkGilead SciencesHepatitis CPharmaceuticalPricingSovaldiUSA

1 to 25 of 6955 results

Back to top